ABSTRACT Tracheal defects caused by trauma, malignancy, congenital anomalies, or prolonged intubation remain a significant clinical challenge, particularly for long‐segment replacements where conventional solutions such as autologous tissue grafts, allografts, and synthetic implants have shown limited long‐term success. Tissue‐engineered tracheas (TETs) have emerged as a promising alternative by integrating advances in scaffold design, fabrication techniques, and biological augmentation. Recent progress in scaffold materials, including decellularized natural matrices, synthetic polymers, and hybrid composites, has led to the development of constructs that better mimic the structural and functional properties of the native trachea. Fabrication techniques such as 3D printing, electrospinning, and cell sheet engineering have enabled the production of anatomically precise and patient‐specific grafts. In parallel, biological strategies aimed at promoting vascularization, accelerating epithelialization, and modulating immune responses have significantly improved graft integration and long‐term functionality. Despite these advances, the clinical translation of TETs remains hindered by challenges related to achieving adequate vascularization, complete epithelialization, and immune modulation. Additionally, regulatory approval requires rigorous preclinical validation, standardized manufacturing protocols, and long‐term safety assessments to ensure consistent clinical outcomes. As these challenges are addressed through ongoing research, TETs hold the potential to revolutionize the treatment of long‐segment tracheal defects by providing functional, durable, and biologically integrated airway replacements.
Bi et al. (Thu,) studied this question.